Clinical trial • Phase I • Oncology
Clinical trial in Advanced solid tumors | Advanced B-cell lymphomas
Phase I trial for Advanced solid tumors | Advanced B-cell lymphomas. 76 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced solid tumors | Advanced B-cell lymphomas
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 21-10-2025
- First CTIS Authorization Date
- 16-02-2026
Trial design
Phase I trial across 6 sites in Denmark, France, Italy and others.
- Target Sample Size
- 76
Recruitment
- Planned Sample Size
- 76
- Recruitment Window Months
- 27
Geography
- Total Number Of Sites
- 6
- Total Number Of Participants
- 41
Denmark
- Earliest CTIS Part Ii Submission Date
- 09-02-2026
- Latest Decision Or Authorization Date
- 16-02-2026
- Processing Time Days
- 7
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- Rigshospitalet
- Department Name
- Haematology and Phase 1 Unit
- Contact Person Name
- Martin Hutchings
- Contact Person Email
- martin.hutchings@regionh.dk
France
- Earliest CTIS Part Ii Submission Date
- 15-12-2025
- Latest Decision Or Authorization Date
- 16-02-2026
- Processing Time Days
- 63
- Number Of Sites
- 3
- Number Of Participants
- 15
Sites
- Site Name
- Centre Leon Berard
- Department Name
- Medical Oncology
- Contact Person Name
- Sylvain Lamure
- Contact Person Email
- sylvain.lamure@lyon.unicancer.fr
- Site Name
- Institut Curie
- Department Name
- Oncology
- Contact Person Name
- Clémentine Sarkozy
- Contact Person Email
- clementine.sarkozy@curie.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- Département d’Innovations Thérapeutiques et d’essais Précoces (DITEP)
- Contact Person Name
- Vincent Ribrag
- Contact Person Email
- vincent.ribrag@gustaveroussy.fr
Italy
- Earliest CTIS Part Ii Submission Date
- 09-02-2026
- Latest Decision Or Authorization Date
- 23-02-2026
- Processing Time Days
- 14
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Department Name
- Hematology
- Contact Person Name
- Luigi Zinzani
- Contact Person Email
- pierluigi.zinzani@unibo.it
Spain
- Earliest CTIS Part Ii Submission Date
- 09-12-2025
- Latest Decision Or Authorization Date
- 18-02-2026
- Processing Time Days
- 71
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Hematology
- Contact Person Name
- Daniel Morillo Giles
- Contact Person Email
- dmorillo@startmadrid.com
Sponsor
Primary sponsor
- Full Name
- Immunome Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)